Table Of Content

CUMULATIVE INDEX 1992 Volume 19 March AIDS AND HIV INFECTION IN OFFICE PRACTICE, pages 1-264 June SPORTS MEDICINE: MUSCULOSKELETAL PROBLEMS, pages 265-417 September CANCER EPIDEMIOLOGY, PREVENTION, AND SCREENING, pages 419-655 December CANCER DIAGNOSIS AND TREATMENT, pages 657-913 Note: Page numbers of article titles are in boldface type Abdominal strength, evaluation of, in in HIV infection, 48 dancers, 394 neuropsychiatric effects of, 107 Abduction stress test, in knee injury, 355- Adduction stress test, in knee injury, 357 366 Adenoma, colon, progression to cancer, Acanthosis nigricans, in cancer, 739 624-625 Acetaminophen, in cancer, 795-796 Adolescents, HIV infection risk and, 171- Achilles tendon, rupture of, 389 190 tendinitis of, in dancers, 406 attitudes of, 175-179 Acid phosphatase, as tumor marker, in counseling of, 184-185 prostate cancer, 719-720 drug use and, 181 epidemiology of, 172-175 Acquired immunodeficiency syndrome. ethical issues and, 185-186 See also Human immunodeficiency virus homeless, 181-182 infection. interview techniques for, 182-184 appearance of, after latency phase, 8-9 legal issues and, 185-186 vs. CD4 count, 10 preventive education for, 186-187 definition of, 11-12 sexual behavior of, 179-181 indicator diseases for, 12 testing of, 184-185 prognosis of, 10-11 Adrenal insufficiency, in HIV infection, 40 Acrokeratosis paraneoplastica, in cancer, Adrenocorticotropic hormone, excessive 740 secretion of, in cancer, 729 Acromegaly, in cancer, 731 Adriamycin (doxorubicin), in cancer Acromioclavicular joint, injuries of, 278- chemotherapy, 763 Aerobic dance injuries, 394 280 Age. See also Elderly persons; Pediatric Actinic keratosis, 564-565 patients. Actinomycin, in cancer chemotherapy, cancer mortality and, 425 763 cervical cancer incidence and, 590-591 Acyclovir, in herpes simplex virus AIDS. See Acquired immunodeficiency infection, with HIV infection, 77 syndrome; Human immunodeficiency in herpes zoster infection, 53 virus infection. 891 892 CUMULATIVE INDEX 1992 AIDS-related complex, 11 self-medication with, in drug abusers, Alkeran (melphalan), in cancer 130 chemotherapy, 761-762 Antibodies, to HIV, 8, 27-28 Alkylating drugs, in cancer Anticonvulsants, in cancer, as adjuvant chemotherapy, 760-762 analgesic, 803 Alpha-fetoprotein, as tumor marker, in Antidepressants, in cancer, as adjuvant gastric carcinoma, 716 analgesics, 803 in germ cell tumors, 718 in HIV-related disorders, 113-115 in hepatocellular carcinoma, 717-718 Antidiuretic hormone, inappropriate in metastasis of unknown origin, 751 secretion of, in cancer, 729-730 in ovarian cancer screening, 616 Antiemetics, in chemotherapy side effects, Alpha-L-fucosidase, as tumor marker, in 776-777 hepatocellular carcinoma, 718 Antiestrogens, in cancer chemotherapy, Alternative therapy, for HIV infection, 54, 767 87-96 Antihistamines, in chemotherapy side Amebiasis, in gay patient, 196-197 effects, 776 Aminoglutethemide, in cancer in HIV-related anxiety, 113 chemotherapy, 766 Antimetabolites, in cancer chemotherapy, Amitriptyline, in cancer, as adjuvant 765-766 analgesic, 803 Antioxidants, dietary, in cancer Anadrol, in cancer chemotherapy, 767 prevention, 486 Anal intercourse, trauma from, 198-199 Antiretroviral therapy, in HIV infection, Androgens, in cancer chemotherapy, 766- 6-7, 46-47. See also Zidovudine. 767 Anus, cancer of, in gay patient, 194-195 Anemia, in cancer, 734 Anxiety, in HIV infection, 103-104, 113 in leukemia, 855-856 Apley’s compression test, in knee injury, Angiomatosis, bacillary epithelioid, in HIV infection, 77 Apprehension test, in knee injury, 360 Ankle injuries, 377-392 in shoulder injury, 267-269 Achilles tendon rupture, 389 Arterial portography, in liver metastasis, anatomic considerations in, 377-379 701-702 avulsion, 381 Arthrography, of ankle, 387 classification of, 388 of shoulder, 272 contusion, 388 Asbestos, as carcinogen, 470-471 differential diagnosis of, 388-389 Asparaginase, in cancer chemotherapy, evaluation of, 382 768 eversion, 380-381 Aspergillosis, in HIV infection, 61 examination in, 383, 385-386 Aspiration, of knee, in injury, 362-363 flexor hallucis longus tendinitis, 389, Aspiration biopsy, fine needle, in cancer 407 diagnosis, 667-669 in dancers, 394, 403, 405, 407 in lung cancer, 678 inversion, 379-380 Aspirin, in cancer, 795-796 ligamentous structures in, 377-379 Astrocytoma, 880 pathogenesis of, 379-382 Athroscopy, in knee injury, 373-374 peroneal tendinitis, 389 Autoimmune hemolytic anemia, in peroneal tendon subluxation, 388-389 cancer, 734 radiography of, 386-388 Autonomy, as ethical principle, 822-823 strain, 388 Axillary nodes, metastasis to, from synovitis after, 389 unknown primary tumor, 753 treatment of, 390 5-Azacytidine, in cancer chemotherapy, Ankle movement, in dancers, evaluation 765 of, 394 Azidothymidine. See Zidovudine. Anorectal disorders, in gay patient, 194— AZT. See Zidovudine. 195, 198-199 in HIV infection, 65-66 Anterior drawer test, in ankle injury, 385- 386 B lymphocytes, HIV effects on, 5-6 in knee injury, 356-358 Bacillary epithelioid angiomatosis, in HIV Antibiotics, in cancer chemotherapy, 763- infection, 77 764 Back injuries, in dancers, 405-406 CUMULATIVE INDEX 1992 893 Ballet injuries. See Dance injuries. Brain, HIV infection of, 4, 40-41, 69-74, Barbiturates, in chemotherapy side 98. See also under Neuropsychiatric effects, 776 disorders. Barium enema, in colorectal cancer, 631- leukemic infiltration of, 854-855 632, 687-688 metastasis to, imaging of, 707-709 Basal cell carcinoma, 563-564 tumors of, in pediatric patients, 432, Bazex’s disease, in cancer, 740 879-881 BCNU (bischloroethyl nitrosourea), in Brainstem glioma, 880 cancer chemotherapy, 762 Breast cancer, biopsy in, needle Behavioral therapy, in cancer pain, 804 localization for, 694 Beneficence, as ethical principle, 823 body fat distribution and, 485-486 Benzodiazepines, in chemotherapy side chemotherapy for, 770 effects, 776 diagnosis of, 690-695 in HIV-related anxiety, 113 epidemiology of, 575-576 Bereavement, in cancer death, 818 imaging in, 690-695 Beta—2-microglobulin, as laboratory in elderly persons, 454-456, 458 predictor, in HIV infection, 10, 45-46 in situ, 583-584 Beta carotene, in cancer prevention, 486 incidence of, 422 Biceps tendinitis, 294 mammography in. See Mammography. Bile acids, as carcinogens, 488 metastasis from, 753 Biliary tract disease, in HIV infection, 66- mortality in, 429 67 nutrition and, 482-484 Bioethics. See Ethics. obesity and, 485-486 Biofeedback, in patellofemoral joint screening for, 575-588, 691 dysfunction, 336 age considerations in, 583 Biological agents, in cancer clinical examination in, 578 chemotherapy, 767-768 controversies in, 583-584 Biomechanics, of elbow injuries, 284-285 epidemiology and, 575-576 of patellofemoral joint dysfunction, growth characteristics and, 519 336-337 in elderly persons, 458 Biopsy, breast, needle localization for, 694 in situ carcinoma and, 583-584 fine needle, 667-669, 678 interval for, 583 in cancer diagnosis, 667-669 mammography in, 458, 578-582 in cancer management, 674 participation in, 584-585 lung, 678 prostate, 685 procedures for, 576-580 Bischloroethyl nitrosourea, in cancer recommendations for, 585-586 chemotherapy, 762 self-examination in, 576-577 Bladder cancer, chemotherapy for, 770 sonography in, 580 Bleomycin, in cancer chemotherapy, 763 staging of, 695 Blood, occult. See Occult blood testing. tumor markers for, 718-719 Blood disorders, in HIV infection, 39-40 Breast Cancer Detection Demonstration in paraneoplastic syndromes, 732-735 Project, 582 Blood tests, in cancer diagnosis, 665-666 Breast feeding, HIV transmission by, 21, Blood transfusion, HIV transmission by, 159-160 22 Bullous lesions, in cancer, 740 in hemophiliacs, 173, 178-179 Burkitt’s lymphoma, viral etiology of, 475 Bone, Ewing’s sarcoma of, 885-886 Burnout, in AIDS patient care providers, metastasis to, imaging of, 702-707 250-252 osteosarcoma of, 884-885 Busulfan, in cancer chemotherapy, 760 Bone marrow, depression of, in Butylated hydroxyanisole, in cancer chemotherapy, 775 prevention, 488 transplantation of, in leukemia, 859-860 Butyrophenones, in chemotherapy side in lymphoma, 864 effects, 776 Bone scan, in cancer, in pediatric patients, 875 metastatic, 702-706 of unknown origin, 751 CA 15-3 antigen, as tumor marker, in Bowen’s disease, 565-567, 740 breast cancer, 718-719 “Boxer’s elbow,” 292 in metastasis of unknown origin, 750 894 CUMULATIVE INDEX 1992 CA 19-1 antigen, as tumor marker, in future trends in, 437-438 metastasis of unknown origin, 750 goals of, 437 CA 19-9 antigen, as tumor marker, in implications of, 429-431 colorectal cancer, 717 in adolescents, 431-432 in pancreatic cancer, 717 in elderly persons, 451-452 CA 54/61 antigen, as tumor marker, in in pediatric patients, 431-432 gynecologic cancer, 720 mortality, 423-430, 437-438 CA 72-4 antigen, as tumor marker, in nutrition and, 482-483 gastric carcinoma, 716 population considerations in, 515-517 CA 125 antigen, as tumor marker, in prostate, 637 gynecologic cancer, 720 risk factors and, 467-468 in hepatocellular carcinoma, 718 ethical issues in, 821-833 in ovarian cancer screening, 615-616 family and, 835-852 CA 242 antigen, as tumor marker, in adjustment strategies of, 840-843 colorectal cancer, 717 assessment of, 844-846 in pancreatic cancer, 717 cancer risk factors for, 786 CA M29 antigen, as tumor marker, in communication within, 843 gynecologic cancer, 720 dying patient care by, 809-810 Cachectic paraneoplastic syndromes, 741- ethical issues and, 831-832 742 imminent death and, 817-818 CAGE questionnaire, in drug abuse impact on, 840-844 screening, 134-135 in terminal phase, 843-844 Calcitonin, excessive secretion of, in interventions for, 846-849 cancer, 731 life cycle of, 837-839 Cancer. See also Leukemias; Lymphoma; normal function of, 836-837 specific site. physical reactions to, 842 anal, in gay patient, 194-195 physician interaction with, 839-840 blood disorders in, 732-735 role assignment in, 843 bone. See under Bone. gastric. See Stomach cancer. brain, diagnosis of, 707-709 genetic counseling in, 786 breast. See Breast cancer. germ cell tumors, 718, 771 chemotherapy in. See Chemotherapy. growth characteristics of, screening coagulation disorders in, 732-733, 735 and, 517-519 colorectal. See Colorectal cancer. gynecologic. See Gynecologic cancer. control of, definition of, 535-536 hematologic disorders in, 732-735 death from, 817-818. See also subhead: hospice care for, 807-820 terminal phase of. imaging in, bone metastasis, 702-707 diagnosis of, disclosure of, 657-663 brain metastasis, 707-709 imaging in. See subhead: imaging in. breast, 690-695 in childhood. See Cancer, in pediatric colorectal, 687-690 patients. gynecologic, 695-698 in elderly persons, 452 in pediatric patients, 875 pathology in, 665-669 liver metastasis, 698-702 report of, 670-672 lung, 677-681, 707-709 tumor markers in. See Tumor markers. prostate, 681, 683-687 disclosure of, 657-663 in elderly persons, 451-463, 591 disfigurement in, adjustment to, 841- in pediatric patients, 431-432, 871-889 842 P brain tumors, 879-881 doubling time in, 517-518 diagnosis of, 873-876 early diagnosis of, definition of, 535- disclosure of, 659 536 pathogenesis of, 872-873 emotional aspects of, 539, 543-544, 550, solid tumors, 871-889 554 astrocytoma, 880 employment discrimination in, 782 brain, 879-881 endocrine disorders in, 728-731 diagnosis of, 873, 875-876 epidemiology of, 419-441. See also sub- Ewing’s sarcoma, 885-886 head: incidence of. glioma, 880 breast, 575-576 histology of, 876 cervical, 590-594 imaging of, 875 economic status and, 443-450 laboratory evaluation of, 873, 875 CUMULATIVE INDEX 1992 895 medulloblastoma, 880-881 chemical carcinogens, 469-472 neuroblastoma, 881-882 colorectal, 622 osteosarcoma, 884-885 dietary, 483-485 pathogenesis of, 872-873 epidemiology and, 467-468 prognosis for, 871-872 genetic, 468-469 retinoblastoma, 884 radiation, 472-475 rhabdomyosarcoma, 883 smoking, 469-470, 592 signs and symptoms of, 873 viral infections, 475-476, 592-594 staging of, 876 school problems in, 782 treatment of, 876-879 screening for, 430, 432-437, 535-556 staging of, 876 access to care and, 551-553 survivors of, 779-780, 782 approaches to, 514-515 treatment of, 876-879 barriers to, 535-541, 548-552 Wilms’ tumor, 432, 882 breast, 575-588 incidence of, 420-423, 437-438 cervical, 589-606 cervical, 589-590 colorectal, 621-635 geographic location and, 427-429 consultation base for, 540-541, 547 in family practice, 539 continuity and discontinuity of care informed consent in, 659-661, 826-827 and, 541-543, 549, 552-553 knowledge deficit on, 539-540, 550 cost/benefit analysis of, 531 late physical effects of, 780-781 criteria for, 526-529 liver. See under Liver. definitions related to, 514-516, 535 lung. See Lung cancer. disease orientation and, 537-538, marital status and, 782-783 548-549 metastatic. See Metastasis. distrust of health care industry and, mortality in, 423-430, 437-438 549-550 cervical, 429, 589-590 education on, 545-546, 553 economic status effects on, 447 emotional aspects of, 539, 543-544, smoking and, 495-496 550, 554 natural history of, cervical, 595-596 ethics of, 526 in elderly persons, 452-453 evaluation of, 526-531 neurologic symptoms in, 735-739 financial aspects of, 538, 544-545, 553 pain management in, 793-805 gynecologic, 589-606, 607-620 drugs for, 795-803 in elderly persons, 457-459 nonpharmacologic, 803-804 incentives for, 541-548, 552-554 pain assessment in, 794-795 interval between screenings, 528-529 pain causes in, 794 knowledge deficit on, 539-540, 550 psychosocial components of, 795 lead time bias in, 530, 576 pancreatic. See Pancreatic cancer. legal issues in, 546-547 paraneoplastic syndromes in. See Para- length bias in, 530-531, 576 neoplastic syndromes. low incidence and, 539 physician attitudes toward, 657-658 lung cancer, 678 positive meaning found in, 829-830 office-based, 665-669 presymptomatic phase of, screening in, physician attitudes toward, 543 518-519 populations for, 515-517 prevention of, dietary factors in, 486- positive predictive value in, 520-523, 489 626 nutrition in, 481-491 predictive values for, 436-437, 626 skin, 557-574 principles of, 513-533 smoking cessation in, 493-511 procrastination in, 550 prognosis for, hospice care and, 816 professionalism in, 542 prostate. See Prostate cancer. prostate, 518-519, 637-649 psychosocial issues in, 781-783 protocols for, 538, 544, 549, 552 quality of life in, 783-784 recommendations for, 513-514, 526— relatives’ malignancy risk and, 786 527 reproductivity and, 785-786 record keeping in, 547-548, 554 risk factors for, 465-479 reluctance to, 540 body fat distribution, 485-486 results of, 435 carcinogenesis and, 466-467 self-selection bias in, 529-530 cervical, 590-594 sensitivity in, 523-524 896 CUMULATIVE INDEX 1992 Cancer (Continued) oral, 38, 52-53 skin, 557-574 vaginal, 52 socioeconomic factors in, 551 Cannabinoids, in chemotherapy side specificity in, 523-525 effects, 776 support staff attitudes toward, 540, Carboplatin, in cancer chemotherapy, 763 547 Carcinoembryonic antigen, as tumor tests for, 433-434, 519-525 marker, in gastrointestinal time constraints on, 538 cancer, 716-718 tumor growth and, 517-519 in lung cancer, 719 validity of, 434-436 in metastasis of unknown origin, 750 second malignant neoplasms in, 784— Carcinogenesis, chemical, 469-472 785 laboratory assays for, 471-472 self-concept in, 782 radiation, 472-475 sexual dysfunction in, 785-786 stages of, 481-482 socioeconomic factors in, 443-450, 551, steps of, 466-467 591, 786-787 viral, 475-476, 592-594 spirituality and, 817, 830-831 Carcinoma, basal cell, 563-564 staging of, breast, 695 hepatocellular. See Hepatocellular carci- colorectal, 688-689 noma. gynecologic, 696-697 squamous cell, cervical, 595-596 Hodgkin's disease, 866-867 skin, 568-569 lung, 679 Carcinomatosis, meningeal, imaging of, lymphoma, 863 pediatric solid tumors, 876 Case management, for AIDS patients, prostate, 685 235-237 survivors of, 779-791 Castanospermine, in HIV infection, 6 genetic counseling of, 786 Cavernous hemangioma, imaging of, 700- late physical effects in, 780-781 701 psychosocial issues and, 781-783 CCNU (cyclohexylchloroethy] quality of life for, 783-784 nitrosourea), in cancer chemotherapy, recommendations for, 787-788 762 relatives’ malignancy risk and, 786 Ceftriaxone, in proctitis, 196 reproductivity in, 785-786 in syphilis with HIV infection, 124 second malignancy in, 784-785 Central nervous system. See also Brain; sexual dysfunction in, 785-786 Spinal cord. socioeconomic factors and, 786-787 HIV infection manifestations in, 4, 40- terminal phase of. See also Hospice care. 41, 69-74 family coping with, 843-844 from primary viral invasion, 98 pain management in, 802 leukemia involvement of, 854-855 treatment limitation in, 831-832 paraneoplastic syndromes affecting, 736 treatment of. See also subhead: survi- tumors of, in pediatric patients, 432 vors of. Cerebellar degeneration, as paraneoplastic decision making in, 824-826, 828 syndrome, 736 drugs in. See Chemotherapy. Cervical cancer, 589-606 economic status effects on, 446-447 cervicography in, 602 in childhood. See Cancer, in pediatric clinical presentation of, 594 patients. colposcopy in, 601-602 in elderly persons, 453-454 diagnosis of, 695-698 informed consent in, 826-827 epidemiology of, 590-594 late physical effects of, 780-781 imaging of, 695-698 limitation of, 831-832 incidence of, 589-590 pathologist role in, 669-674 mortality in, 429, 589-590 physician bias in, 828-829 natural history of, 595-596 quality of life and, 783-784 risk factors for, 590-594 truthtelling in, 826-827 screening for, 433-434, 596-601 tumor markers in. See Tumor markers. in presymptomatic stage, 518-519 unknown primary source in. See Metas- precursor lesions detected in, 590 tasis, of unknown origin. staging of, 594 Candidiasis, in HIV infection, esophageal, tumor markers in, 720 63 viral etiology of, 476, 592-594 CUMULATIVE INDEX 1992 897 Cervical intraepithelial neoplasia, 595-596 Clinical trials, of HIV-related drugs, 54, in HIV infection, 52, 165 90-94 Cervical lymph nodes, metastasis to, from Clonidine, in heroin abuse withdrawal unknown primary tumor, 751-753 maintenance, 141-142 Cervical smear, for Pap test, 666-667 in smoking cessation, 503 Cervicography, 602 Clotrimazole, in oral candidiasis, 53 Chemical carcinogenesis, 469-472 Coagulation disorders, in cancer, 732-733, Chemotherapy, 759-778 735 combination, in HIV infection, 48 Cocaine abuse, 133-134, 144-145 drugs for, alkylating, 760-762 Coccidioidomycosis, in HIV infection, 61 antibiotics, 763-764 Collateral ligaments, of knee, injuries of, antimetabolites, 765-766 lateral, 369-370 asparaginase, 768 medial, 368-369 biologicals, 767-768 testing of, 355-366 combinations of, 769-774 Colonoscopy, in cancer screening, 631 concurrent measures with, 775-777 Colorectal cancer, 621-635 curability and, 775 chemotherapy for, 770-771 dimethyltriazenoimidazolecarbox- diagnosis of, 687-690 amide, 768 imaging of, 687-690 emotional support with, 777 incidence of, 422-423 hexamethylmelamine, 768 metastasis from, imaging of, 701-702 historical aspects of, 759-760 mortality in, 428-429 hormonal agents, 766-767 nutrition and, 482-485 hydroxyurea, 768-769 prevention of, dietary fiber in, 488 investigational, 769 progression from adenomatous polyps, mitotane, 769 624-625 mitotic inhibitors, 764-765 risk factors for, 622 nitrosoureas, 762 screening for, 434, 687 platinum compounds, 762-763 barium enema studies in, 631-632 procarbazine, 769 colonoscopy in, 631 resistance to, 775 digital examination in, 625 side effects of. 775-777 in daily practice, 632 in Hodgkin's disease, 867-868 occult blood testing in, 520, 625-629 in leukemia, 858-859 positive predictive value in, 520, 626 in lymphoma, 864 protocol for, 538 AIDS-related, of central nervous sys- recommendations for, 622 tem, 74 sigmoidoscopy in, 629-631 in metastasis of unknown origin, 754 staging of, 688-689 in pediatric patients, 876-879 treatment of, imaging after, 689-690 in leukemia, 858-859 tumor markers in, 716-717 in lymphoma, 864 Colposcopy, 601-602 side effects of, 860-861 Community-based services, for AIDS quality of life and, 783-784 patients. See under Acquired second malignant neoplasms from, 785 immunodeficiency syndrome. Chlamydia infection, in gay patient, 197 Computed tomography, in cancer, brain Chlorambucil, in cancer chemotherapy, metastasis, 707—709 761 colorectal, 689-690 Chloroma, 855 gynecologic, 696-698 Cholangiopathy, in HIV infection, 67 in pediatric patients, 875 Chondral fractures, of knee, 374 liver metastasis, 698-702 Chondromalacia, of patella, 325 lung, 678, 680, 709 Chromosomal abnormalities, in cancer, metastasis of unknown origin, 751 468-469 prostate, 686 Chronic inflammatory demyelinating of patellofemoral joint, 319 polyneuropathy, in HIV infection, 105 Condoms, in HIV prevention, 26, 178, Cigarette smoking. See Smoking. 180, 186-187 Cisplatin, in cancer chemotherapy, 762- Confidentiality, in HIV infection, 25, 207- 763 209, 224-226 Clindamycin, in Pneumocystis carinii Constipation, from opioids, 801 pneumonia, 60 Contraception, in adolescents, 179-180 898 CUMULATIVE INDEX 1992 Contraception (Continued) overuse, 405-409 in HIV-positive patients, 165-166 prevention of, 409 Contusion, of ankle, 388 shin splints, 407 Coronary heart disease, smoking and, significance of, 393 495-496 talocrural joint impingement, 407 Corticosteroids, in cancer, as adjuvant terminology related to, 399 analgesic, 802-803 toes, 394, 405, 407-408 in chemotherapy side effects, 777 types of dance and, 394 in HIV infection, neuropsychiatric ef- Dapsone, in Pneumocystis carinii fects of, 107 pneumonia, 49, 60, 162 in patellofemoral joint dysfunction, 335 Daunorubicin, in cancer chemotherapy, in Pneumocystis carinii pneumonia, 60 764 Counseling, in HIV infection. See under “Dead arm syndrome,” in shoulder Human immunodeficiency virus infection. injury, 274 Cranial neuropathy, in HIV infection, 104 Death, in cancer. See Cancer, terminal Craniospinal irradiation, in phase of. medulloblastoma, 881 Decision making, ethics in, 824-826, 828 Cross-arm test, in shoulder injuries, 269 Delirium, in HIV infection, 102, 112-113 Crow-Hop method, for elbow therapy, Dementia, in HIV infection, 41, 100-102 300 Depression, in cancer survivors, 782 Cruciate ligaments, injuries of, anterior, in HIV infection, 103-104, 113-114 363-367 Dermatologic paraneoplastic syndromes, posterior, 367-368 739-740 Cryptococcosis, in HIV infection, Dermatomyositis, in cancer, 738-739 meningitis, 72-73 Desipramine, in cancer, as adjuvant pulmonary, 61 analgesic, 803 Cushing’s syndrome, in cancer, 729 Dexamethasone, in cancer, as adjuvant Cyclohexylchloroethy! nitrosourea, in analgesic, 803 cancer chemotherapy, 762 Dextran sulfate, in HIV infection, 6, 94 Cyclophosphamide, in cancer Dextroamphetamine, in HIV-related chemotherapy, 761 encephalopathy, 112 Cytadren (aminoglutethemide), in cancer Diaphonography, in breast cancer, 695 chemotherapy, 766 Diarrhea, in gay patient, 196-197 Cytomegalovirus infection, with HIV in HIV infection, 40, 64-65 infection, esophageal, 63 Didehydro-dideoxythymidine, in HIV gastric, 64 infection, 6 retinitis, 68—69 Dideoxycytidine, in HIV infection, 6, 47- Cytosine arabinoside, in cancer 48 chemotherapy, 765 Dideoxyinosine, in HIV infection, 6, 47 Cytoxan (cyclophosphamide), in cancer Diet. See Nutrition. chemotherapy, 761 Diethylstilbestrol, in cancer chemotherapy, 767 Digital rectal examination, in cancer screening, colorectal, 625 Dactinomycin, in cancer chemotherapy, prostate, 642-643 7 Dimethyltriazenoimidazolecarboxamide, Dance injuries, 393-411 in cancer chemotherapy, 768 Achilles tendinitis, 406 Disseminated intravascular coagulation, in activity regimen for, 400 cancer, 733 acute, 400-401, 403, 405 Distal symmetric polyneuropathy, in HIV ankle, 394, 403, 405, 407 infection, 105 back, 405-406 DNA studies, in cancer management, 673 dancer evaluation and, 394-399 Doxorubicin, in cancer chemotherapy, 763 epidemiology of, 394 Doxycycline, in chlamydia infection, 197 foot, 394, 405, 408-409 in proctitis, 196 fractures, 403, 405, 407 Drawer tests, in ankle injury, 385-386 hip, 406 in knee injury, 356-360 in males, 394, 401, 405 Drug(s), dependence on, vs. abuse, 131 knee, 403, 406 in HIV infection. See Human immunode- medication use in, 409-410 ficiency virus infection, therapy for. CUMULATIVE INDEX 1992 899 interactions of, in HIV-infected drug anterior, 294-295 abusers, 129-130 biomechanics of, 284-285 occult blood testing results and, 626- dislocations, 296-297 627 electrodiagnostic studies of, 297 Drug abuse, 119-156 fractures, 291, 295-296 as chronic disease, 131-132 hyperextension, 292, 294-295 categories of, 130-131 lateral compartment, 289-291 cocaine, 133-134, 144-145 medial compartment, 285-289 definition of, 131 occupational therapy in, 298-300 denial of, 135, 137, 139 pediatric, 296-297 diagnosis of, 134-137 physical therapy in, 298-300 epidemiology of, 119, 131 posterior, 291-294 health maintenance screening in, 137- radiocapitellar joint, 290-291, 296 139 radiologic evaluation of, 297 heroin, 132-133, 140-144 Elderly persons, cancer in, 451-463 HIV infection with, bacterial infections breast, 454-456, 458 and, 121-122 care delivery in, 459-460 disease spectrum in, 120 cervical, 591 drug effects vs. HIV effects in, 128- diagnosis of, 452 129 epidemiology of, 451-452 drug interactions in, 129-130 lung, 456-458 hepatitis and, 124-125 natural history of, 452-453 human T-lymphotropic virus types screening for, 457-458 and, 126-127 treatment of, 453-454 in adolescents, 171, 173-174, 181 Electromyographic biofeedback, in malignancies and, 127 patellofemoral joint dysfunction, 336 neurologic disease and, 125-126 Electron microscopy, in cancer physical examination in, 137 management, 672-673 pregnancy and, 157-158 ELISA (enzyme-linked immunosorbent psychosocial issues in, 147-148 assay), for HIV infection, 27 self-medication problems in, 130 Elspar (asparaginase), in cancer sexually transmitted diseases and, chemotherapy, 768 123-124 Embolism, pulmonary, in cancer, 733 tuberculosis and, 122-123 Employment discrimination, of cancer in HIV transmission, 21, 26 survivors, 782 management issues in, in hospitaliza- Encephalitis, limbic, in cancer, 736 tion, 145-146 toxoplasmic, in HIV infection, 70-72 pain, 146-147 Encephalopathy, in HIV infection, 70 psychosocial issues, 147-148 subacute, 100-102, 111-112 screening for, 134-137 Endocarditis, bacterial, in drug abuse, 122 treatment modalities for, 139-140 thrombotic, in cancer, 733 vs. drug dependence, 131 Endocrine paraneoplastic syndromes, withdrawal from, management of, 141- 728-731 142, 145 Endometrial cancer, diagnosis of, 695-698 DTIC (dimethyltriazenoimidazole- imaging of, 695-698 carboxamide), in cancer screening for, 611-612 chemotherapy, 768 Endurance training, in patellofemoral Ductography, in breast cancer, 695 joint dysfunction, 334 Dying, of cancer. See Cancer, terminal Enema, barium, in colorectal cancer, 687- phase of. 688, 690 Dysphagia, in HIV infection, 63 in colorectal cancer detection, 631-632 Dysplastic nevus syndrome, 570-571 Entamoeba histolytica infection, in gay patient, 196-197 Enteritis, in gay patient, 196-197 Entitlement advocacy, for AIDS patients, Eaton Lambert syndrome, in cancer, 736, 229-230 738 Enzyme-linked immunosorbent assay, for Economic factors. See Socioeconomic factors. HIV infection, 27 Elbow injuries, 283-302 Epstein-Barr virus infection, as cancer anatomic considerations in, 283-284 risk, 475, 861-862 900 CUMULATIVE INDEX 1992 Erythrocytes, aplasia of, in cancer, 734 Fish oils, in cancer prevention, 484 Erythrocytosis, in cancer, 734-735 Flavones, in cancer prevention, 488 Esophagus, cancer of, chemotherapy for, Flexibility training, in patellofemoral joint 771 dysfunction, 333 disease of, in HIV infection, 63-64 Flexor hallucis longus tendinitis, 389 Estrogens, as breast cancer risk, 485-486 in dancers, 407 in cancer chemotherapy, 767 Flow cytometry, in cancer diagnosis, 665- receptors for, as tumor marker, in me- 666 tastasis of unknown origin, 750 Fluconazole, in cryptococcal meningitis, Ethics, 821-833 72-73 concepts in, 823-824 in oral candidiasis, 53 in cancer care, 826-832 5-Flucytosine, in cryptococcal meningitis, decision making in, 828 72 informed consent in, 827 Fluorouracil, in cancer chemotherapy, positive meaning and, 829-830 765-766 spiritual transcendence and, 830-831 Fluoxetine, in HIV-related depression, 114 subjective bias in, 828-829 Flutamide, in cancer chemotherapy, 767 treatment limitations and, 831-832 Foot, alignment of, in patellofemoral joint truthtelling in, 826-827 dysfunction, 317 in cancer screening, 526 injuries of. See also Ankle injuries. in decision making, 824-826 in dancers, 394, 405, 408-409 in HIV infection, 203-216 Fractures, ankle, 403 confidentiality and, 207-209 “dancer's” (first metatarsal), 405 dilemma evaluation and, 205-206 elbow, 291, 295-296 in adolescents, 185-186 in dancers, 403, 405, 407 partner notification, 29-30, 209-210 knee, 323-324, 374 patient treatment preferences and, patellar, 323-324 210-211 pathologic, in cancer pain, 804 principles of, 204-205 toes, 405 risk-group identification and, 207-209 Frozen section, in cancer management, transmission to/from health care 672 workers and, 211-213 Functional disorders, in HIV infection, practice of, 824-826 103-104 principles in, 822-823 Functional training, in patellofemoral joint Etoposide, in cancer chemotherapy, 765 dysfunction, 334 Ewing’s sarcoma, 885-886 Fungal pneumonia, in HIV infection, 61 Exercise, in patellofemoral joint dysfunction, 332-334 External rotation stress test, in ankle injury, 386 Gait analysis, in patellofemoral joint Eye disorders, in HIV infection, 38, 67-69 dysfunction, 338 Gallium scan, in Pneumocystis carinii pneumonia diagnosis, 59 Gastric cancer. See Stomach cancer. Family, of cancer patient. See Cancer, family and. Gastrointestinal disorders, in HIV Fat, body, cancer risk and, 485-486 infection, 40, 63-67 dietary, cancer prevention and, 483-484 Gay bowel syndrome, 196 Fat pad impingement, in knee, 327-328 Gay patients, 191-201 Fatigue, in HIV infection, 114-115 anorectal conditions in, 194-196 Febrile neutrophilia dermatosis, 740 enteritis in, 196-197 Fecal occult blood testing. See Occult blood hepatitis in, 198 testing. HIV infection in, in adolescent popula- Fever, paraneoplastic syndromes and, 741 tion, 180-181 Fiber, dietary, in cancer prevention, 488 medical issues involving, 194-198 Fibular compression test, in ankle injury, pharyngitis in, 196-197 386 psychologic issues involving, 192-194 Fine needle aspiration, in cancer sexual behavior of, 198-199 diagnosis, 667-669 social issues involving, 192-194 in lung cancer, 678 Gender, cancer mortality and, 424-425